Insights

Strategic Leadership Telo Genomics recently appointed John Farlinger as CEO and chairman, signaling a governance and strategic shift that may unlock partnership and investment opportunities with clinical providers, biotech firms, and research institutions seeking validated leadership to accelerate commercialization of telomere-based diagnostics.

Clinical Validation With over 150 peer reviewed publications and 25 clinical studies involving more than 3,000 patients, there is a strong track record that can be leveraged to engage hospitals, cancer centers, and neurology clinics as potential customers or collaborators for MRD and prognostic telomere-based assays.

Focused Offerings Lead application Telo-MM targeting Multiple Myeloma positions the company for partnerships with hematology/oncology groups and pharmaceutical developers aiming to integrate prognostic tools into treatment workflows and clinical trial enrichment.

Regulatory & Market Access Active presence in major hematology conferences (ASH) and ongoing clinical presentations create opportunities to sponsor or co-host educational events, pilot programs, or data-sharing initiatives with healthcare networks seeking evidence-based diagnostic solutions.

Financial & Partnership Momentum Recent executive appointments for CFO and CEO, combined with revenue under one million and a strategic emphasis on liquid biopsy platforms, indicate a ripe window for strategic partnerships, licensing, or contract research collaborations to scale development and commercialization.

Similar companies to Telo Genomics

Telo Genomics Tech Stack

Telo Genomics uses 8 technology products and services including Amazon Web Services, WordPress, Google Workspace, and more. Explore Telo Genomics's tech stack below.

Media & News

Telo Genomics's Email Address Formats

Telo Genomics uses at least 1 email format:
Telo Genomics Email FormatsExamplePercentage
First.Last@telodx.comJohn.Doe@telodx.com
100%

Frequently Asked Questions

What is Telo Genomics's official website and social media links?

Minus sign iconPlus sign icon
Telo Genomics's official website is telodx.com and has social profiles on LinkedIn.

How much revenue does Telo Genomics generate?

Minus sign iconPlus sign icon
As of November 2026, Telo Genomics's annual revenue is estimated to be <$1M.

What is Telo Genomics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Telo Genomics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Telo Genomics have currently?

Minus sign iconPlus sign icon
As of November 2026, Telo Genomics has approximately 9 employees across 1 continents, including North America. Key team members include Laboratory Director (iso 15189): Y. S., Research And Development Manager: A. A. and Laboratory Manager: Z. H. Explore Telo Genomics's employee directory with LeadIQ.

What industry does Telo Genomics belong to?

Minus sign iconPlus sign icon
Telo Genomics operates in the Biotechnology Research industry.

What technology does Telo Genomics use?

Minus sign iconPlus sign icon
Telo Genomics's tech stack includes Amazon Web Services, WordPress, Google Workspace, Font Awesome, Webflow, PHP, Cloudflare Bot Management and Vimeo.

What is Telo Genomics's email format?

Minus sign iconPlus sign icon
Telo Genomics's email format typically follows the pattern of First.Last@telodx.com. Find more Telo Genomics email formats with LeadIQ.

When was Telo Genomics founded?

Minus sign iconPlus sign icon
Telo Genomics was founded in 2014.
Telo Genomics logo

Telo Genomics

Biotechnology ResearchOntario, Canada2-10 Employees

Telo Genomics develops diagnostic and prognostic tools based on telomere analysis, with a focus on liquid biopsy applications for oncology and neurological diseases. The approach combines quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to identify disease-associated genetic instability, aiming to yield simple, accurate products for pathologists, clinicians, academic researchers and drug developers. Based in Toronto, Ontario, the company operates with a small team and is advancing a lead application called Telo-MM to provide actionable information to medical professionals treating Multiple Myeloma. Its work is supported by a substantial body of peer‑reviewed publications and clinical studies involving thousands of patients across several cancers and Alzheimer’s disease. In March 2026, the company appointed John Farlinger as chief executive officer and chairman.

Section iconCompany Overview

Website
telodx.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
2-10

Section iconFunding & Financials

  • <$1M

    Telo Genomics's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.